Literature DB >> 9802810

Hyperbaric oxygen therapy for intestinal obstruction in children: an exceptional experience in a compromised child.

Y Ohno1, T Kanematsu.   

Abstract

Intestinal obstruction in a 2-year-old girl with a histologically proven diagnosis of retroperitoneal yolk sac carcinoma developed after the second course of anticancer chemotherapy. Nonoperative treatment was not effective. Because the patient had fallen into a state of chemotherapy-induced myelosuppression, surgery was ruled out. Thus, hyperbaric oxygen therapy was the next treatment of choice. It was performed twice under hyperbaric oxygen conditions at 2.8 atmospheric pressure for 111 minutes. After the procedure, her general status recovered well. The air-fluid level disappeared on the radiograph, and no adverse effects were observed. Later, a surgical removal of the primary tumor was performed successfully, but an intestinal resection was not required. This is the first instance in which we performed hyperbaric oxygen therapy on a child in the management of an intestinal obstruction. Based on the successful outcome in this case, hyperbaric oxygen therapy is suggested to be a useful adjunct to nonoperative therapy for intestinal obstruction when a patient's overall state does not allow operative intervention.

Entities:  

Mesh:

Year:  1998        PMID: 9802810     DOI: 10.1016/s0022-3468(98)90494-8

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  2 in total

1.  Treatment strategy when using intraoperative peritoneal lavage for perforated appendicitis in children: a preliminary report.

Authors:  Yasuharu Ohno; Junichiro Furui; Takashi Kanematsu
Journal:  Pediatr Surg Int       Date:  2004-06-16       Impact factor: 1.827

2.  Randomized controlled trial of hyperbaric oxygen therapy in adhesive postoperative small bowel obstruction.

Authors:  Yasuyuki Fukami; Satoshi Kobayashi; Ei Sekoguchi; Yasuhiro Kurumiya
Journal:  Langenbecks Arch Surg       Date:  2018-05-28       Impact factor: 3.445

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.